AL	)		

Award Number: DAMD17-97-1-7266

TITLE: The Role of NF-kB in Normal and Transformed Mammary

Epithelium

PRINCIPAL INVESTIGATOR: Fiona E. Yull, Ph.D.

Lawrence D. Kerr, Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center

Nashville, Tennessee 37232

REPORT DATE: August 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

REPORT		Form Approved OMB No. 074-0188  Effections, searching existing and meanishing		
2	nstructions, searchi			
the data needed, and completing and reviewing	this collection of information. Sond comments for Services. Directorale for information Operation			
Management and Budget, Paperwork Paduction  1. AGENCY USE ONLY (Leave blue		3. REPOR	ATES COV	ERED
	August 1999	Annual		93 - 31 Jul 99)
4. TITLE AND SUBTITLE The Role of NF-kB in Epithelium	5. FUNDING NUMBERS DAMD17-97-1-7266			
B. AUTHOR(S)   Fiona E. Yull, Ph.D.   Lawrence D. Kerr, Ph.	. ם			
7. PERFORMING ORGANIZATION	NAME(S) AND ADDRESS(ES)		8. PERFORM	HING ORGANIZATION
Vanderbilt University Nashville, Tennessee 37232			REPORT NUMBER	
fiona.yull@mcmail.	vanderbilt.eu			
9. SPONSORING / MONITORING	AGENCY NAME(S) AND ADDRESS	(ES)	,	ORING / MONITORING
U.S. Army Medical Research ar Fort Detrick, Maryland 21702-	AGENC	Y REPORT NUMBER		
A. CHOOLESSEE				
11. SUPPLEMENTARY NOTES				
123. DISTRIBUTION / AVAILABILIT Approved for Public Re		nlimited	· .	12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Wo	ords)			
mammary cell trans cancer. The NF-k transduction pathy investigating their rohypothesis is that maturation of mammatransformation. We overexpression of the and of a dominant expression of both ty expression alters the	owledge of the molecular formation will provide us B family of transcript ways regulating cell pole in the development of expression of specific Namary epithelium and that have created lines of a family member already inhibitor of NF-kB activities has been confirmed as profile of NF-kB activitions are being characterized.	with information is ion factors are a roliferation, difference normal and transfoliance is not alteration in NF-κ transgenic mice where suspected to be involved in the transpolic stages during during pregnancy	n the fight major of entiation a rmed mam ecessary for B factor hich pertu blved in ca he mamm ng mamma	against human breast component of signal and death. We are amary epithelium. Our or differentiation and expression can effect arb NF-kB levels by reinogenesis (NFkB2) ary gland. Transgene ary development. This
14. SUBJECT TERMS				15. NUMBER OF PAGES 16
Breast Cancer NF-κB, I	rcinoma	16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFIC	CATION	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassifi		Unlimited
NSN 7540-01-280-5500				ndard Form 298 (Rev. 2-89) cribed by ANSI Std. Z39-18 02

# FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.
Where copyrighted material is quoted, permission has been obtained to use such material.
Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.
Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.
☑ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).
For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.
In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.
☐ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.
In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

# TABLE OF CONTENTS

	Page
Front Cover	1
Standard Form (SF) 298	2
Foreword	3
Table of Contents	4
Introduction	5
Body	6
Conclusions	9
References	9
Appendices	11

### INTRODUCTION

Breast cancer is a major cause of cancer mortality for women in the United States and represents the highest rate of new cancer cases for women (1). Knowledge of the molecular signalling pathways involved in the disease process may lead to novel therapeutic strategies. The nuclear factor-kappaB, NF- $\kappa$ B, family of transcription factors play roles in normal functions such as cellular proliferation, differentiation, migration, and programmed cell death (2,3,). They are also implicated in the pathogenesis of cancer, particularly in cells of the immune system (4). However, little is known concerning the precise mechanisms by which this occurs. This research has two major goals. The first is to characterize the role of the transcription factor complex in normal mammary development. The second is to investigate the correlation between the presence of an unusual isoform of NF- $\kappa$ B, NF $\kappa$ B2, and breast adenocarcinomas (5). These questions are being addressed by the generation and characterization of novel transgenic models. One strategy is to block the activity of NF- $\kappa$ B in a transgenic mammary gland and determine the effects of disturbing the normal signalling pathways. The other approach we are employing is to overexpress NF $\kappa$ B2 (p100) to determine whether this protein can induce cellular transformation. Should this prove to be the case we would have generated a novel murine model of mammary tumorigenesis. Our results to date are presented in this review.

### **BODY**

The Rel/NF- $\kappa$ B family of transcription factors represents a distinct subset of nuclear transactivating factors whose activity is inducible via control of its nuclear localization. These enhancer binding proteins are sequestered in the cytoplasm by inhibitory molecules, termed I $\kappa$ Bs. Upon stimulation the I $\kappa$ B is degraded, and the  $\kappa$ B factors are released to enter the nucleus and associate with their cognate DNA binding sites initiating gene transcription (6). Authentic NF- $\kappa$ B is a heterodimer consisting of a 50 kD polypeptide (NF $\kappa$ B1=p50) (7) and a 65 kD polypeptide (RelA=p65)(8) whose primary sequence reveals that the amino-terminal halves of both p50 and p65 are highly homologous to that of the *rel* protein (defining the Rel homology domain, RHD). The RHD encompasses the DNA-binding, dimerization, I $\kappa$ B-binding, basal transcription factor binding, and nuclear localizing domains for these proteins. The carboxy terminal domains of RelA(p65) and cRel contain strong transcriptional transactivation regions (9). In contrast, p50 homodimers bind DNA but are thought to block transcription. In vertebrates, other genes also encode factors which participate in the NF- $\kappa$ B complex and bind to  $\kappa$ B enhancer elements: NF $\kappa$ B2 (p52 and its precursor p100)(10), relb (RelB), and v-rel.

IκBα forms a complex with heterodimeric NF-κB and inhibits the DNA binding activity (11). Following stimulation with a wide variety of distinct agents, the IκB-α protein is phosphorylated on serine residues in the amino-terminus targeting it for destruction by the ubiquitinization/proteosome (26S) degradation pathway, allowing the translocation of NF-κB to the nucleus (11,12,13). A mutation in the IκB-α which removes these serine residues creates an IκB-α protein (termed IκBΔN) behaves as a transdominant inhibitor (14). This has provided an effective means by which to "capture" NF-κB in a cytoplasmic-bound state, thereby preventing its transactivating capabilities (15).

NFκB2 was originally identified via its involvement in a lymphoma-associated chromosomal translocation and is expressed as a 3.2 kilobase mRNA encoding a 100 kDa protein (16). Following proteolytic cleavage to the mature p52 kDa protein, NFκB2-p52 can heterodimerize with all known κB factors and activate the transcription of genes containing κB-enhancer elements. The NFκB2-p100 precursor has activity on its own; p100 behaves as an IκB molecule by sequestering NF-κB complexes in the cytoplasm. In one lymphoid-tumor case reported, overexpressed NFκB2 proteins resulted in abnormal transcriptional regulatory properties (17) suggesting that alteration in NFκB2-regulated gene expression may be causal for transformation. These results suggest that overexpression of either the precursor molecule, p100, or its processed fragment, p52, might alter the normal cellular NF-κB complexes and disregulate cellular homeostasis.

In order to target expression of our transgenes to mammary epithelial cells we have used the promoter of the major whey protein of ruminants, B-lactoglobulin (BLG). Despite the fact that rodents do not have an endogenous BLG gene transgenic mice carrying BLG constructs express specifically and abundantly in the murine mammary gland in an appropriate temporal pattern (18,19). Transgenes using 5' and 3' BLG flanking sequences can target expression of heterologous genes in an appropriate developmental pattern to the mammary (20,21,22). In the previous annual report we had succeeded in generating four lines of transgenic mice targeting IkB $\Delta$ N to the mammary gland, designated MAN for mammary - $\alpha\Delta$ N. We had also produced four lines of mice targeting overexpression of NFkB2 (p100), designated BIN for BLG-inhibitor. This report details further characterization of these lines.

### **Results:**

Specific aim 1 for this proposal was to define the expression pattern of NF-kB factors in normal murine mammary gland development. This aim is being addressed in collaboration with Dana Brantley (awarded a pre-doctoral fellowship - Award Number DAMD17-97-1-7017) and has led to submission of a manuscript (23). See relevant annual report for details.

Specific aim 2 proposed the generation and characterization of two types of transgenics targeting the transdominant inhibitor  $I\kappa B\Delta N$  or  $NF\kappa B2$  expression to the murine mammary gland. A repository of samples has been collected representing a range of developmental stages throughout pregnancy, lactation and regression . These include; virgin, 10.5 and 16.5 dpc (days post coitem, ie. pregnant), 1.5 and 9.5 lactating and 1, 3, 5 and 40 days and 5 weeks post forced wean (at day 10 of lactation) and greater than 1 year. At each stage one gland is removed for histological processing, one is processed in TriZol reagent for RNA extraction, one is flash frozen for isolation of cytoplasmic and nuclear proteins for EMSA, and one gland is preserved for whole mount gland preparation. The particular gland collected for each type of

analysis remains constant. Collection of these stages represents a major time commitment. Transgenic animals are identified by tail biopsy and PCR (as detailed in previous report). Female transgenics are set up in timed matings and day post coitem noted by detection of a vaginal plug. Then animals are sacrificed on the relevant day of pregnancy, lactation etc.

Primary characterization of expression is effected by Northern blot analysis. Results are consistent with those reported in the previous years report with expression of  $I\kappa B\Delta N$  being detected in all four separately derived MAN transgenic lines ie. MAN8, 13, 18 and 19. Expression of p100 has also been detected in three out of four separately derived NF $\kappa$ B2 (p100) lines ie. BIN10, 16 and 18. Offspring from the fourth founder animal, representing the BIN6 line, whilst carrying the transgene have either extremely low expression or a "silent transgene".

Analysis at the level of total RNA has been extended to include investigation of  $\beta$ -casein expression. Although the transgenics appear capable of nursing litters we were interested in whether transgene expression alters milk protein production. We have analysed total RNA samples representing 16.5 dpc, 1.5 days lactation and 9.5 days lactation in all four IkBDN expressing (MAN) lines and in all four BIN lines. Figure 1a shows expression of the p100 transgene and  $\beta$ -casein RNA in mammary samples representing non-transgenic control and lines BIN6, 10, 16, and 18 at day 1.5 of lactation. To detect NFkB2 mRNA, probes of human origin are used that do not cross-react with the endogenous murine NFkB2. Figure 1b shows expression of the IkBDN transgene and  $\beta$ -casein at 16.5 dpc in samples representing control animals and the four MAN lines. In all lines tested and at all stages, the expression of either transgene does not appear to have a significant effect on  $\beta$ -casein expression.

In order to determine whether transgene expression is perturbing normal NF-kB activity, we are analysing the binding activity of protein extracts by electrophoretic mobility shift assay (EMSA). We have started by looking at binding activity at the 16.5 dpc and 9.5 lactating points. The probe used is derived from the HIV-LTR and represents a consensus binding site for NF-kB. Results from the 16.5 dpc stage of the four p100 (BIN) lines have so far shown no significant differences (data not shown). However, analysis of the 9.5 lactation stage detects intriguing differences (Figure 2a). In non-transgenic animals there is barely detectable binding activity during lactation (23). In transgenics a strong shifted complex is present. This complex can be competed for by competitor oligos (+C). Supershift experiments are being attempted using anti-p52, anti-p65 and anti-p50. Whilst no supershifts indicating the presence of p52 or p65 are detected we have been experiencing some technical difficulties with these antibodies such that further investigation is underway to confirm this result. It appears as though the p50 protein represents a large component of the transgenic complex. Preliminary analysis of protein extracts representing the 9.5 day lactation stage of IκBΔN (MAN) transgenics has detected no significant alteration in NF-κB binding activity with no retarded complexes in transgenics or controls (data not shown). However, EMSA of protein samples from the 16.5 dpc stage show subtle changes (Figure 2b). At this stage of pregnancy in a non-transgenic animal there is strong NF-κB binding activity (23). Formation of this complex is inhibited by unlabelled oligo (+C). There appears to be a decrease in the retardation of the complex (or a decrease in the presence of the upper band) in separately derived transgenic lines MAN8 and MAN19. This is interesting in the light of our previous preliminary observation of a decrease in cyclinD1 RNA expression, particularly in these lines.

One of the possible predicted effects of perturbation of NF-κB activity would be to alter proliferation. Intraperitoneal injections of BrdU were administered to animals at day 16.5 of pregnancy. Mice were sacrificed 4 hours later, mammary glands fixed overnight in 4% paraformaldeyde, dehydrated and paraffin embedded sections prepared. Sections were processed using a BrdU staining kit (Zymed) to investigate proliferation of the alveolar epithelial cells (Figures 3+4). The staining of an intestinal sample is included as a control. Proliferating cells were detected in all samples tested with no obvious qualitative differences in proliferation between transgenics and non-transgenic controls. However, some animals exhibited histological differences including a relative decrease in the proportion of alveolar cells populating the "web-like" stroma, a less uniform morphology and an increase in the number of ductal structures. A limited number of samples have been tested. We plan to expand this set and carry out more quantitative measurements by counting relative numbers of proliferating cells.

A continuing concern is the potential for between animal variation (especially as the original mice are B6/D2 (ie.a mixture of both the C57Bl6 and DBA mouse strains). At this stage we are still unable to confirm whether there may be a measure of mosaicism in the expression of the transgenes. We have

attempted to addess this issue using immunohistochemistry of collected paraffin sections. So far our attempts have been unsuccessful due to technical difficulties with the available commercial p52 antibody. We have recently immunized rabbits in an effort to produce a COOH-terminal IkB- $\alpha$  antibody which would be effective for both immunohistochemical and western analyses of the IkB $\Delta$ N (MAN) transgenics. A second paired set of immunizations have been carried out to produce both N-terminal and COOH-terminal antibodies to the p100 protein. These would enable us to effect immunohistochemical and western studies on the BIN lines and to distinguish between the unprocessed p100 form of the protein and the truncated p52 protein.

Mammary epithelial transformation and neoplastic progression, like most cancers, involves cooperative changes in more than one oncogenic or tumor-suppressor pathway. Eventually, it is our intention to cross selected BIN and MAN lines with mice expressing the mouse mammary tumor virus (MMTV) driven-activated *neu* transgene, which reproducibly develop clonal mammary tumors, to determine whether transgene expression can either inhibit or cooperate in producing mammary tumorigenesis. Furthermore, BLG-NFKB2/p100 expressing mice will be interbred with mice expressing the most common p53 mutation (Arg172-His) in human breast cancers to explore the ability of NFxB2 to act as a dominant oncogene in the absence of the well characterized tumor suppressor, p53. All combined, these interbreedings will explore the cooperative nature between these NF-κB components and known mammary carcinogenic signal transduction and genetic pathways in the hopes of better understanding the mechanistic interactions of the oncogenic pathways in human mammary tumorigenesis. The lines of mice described above exist on an FVB strain background whereas our lines are on a B6/D2 background. In order to avoid the potential difficulties of interpreting data on a background consisting of a genetic mix of three strains we have been backcrossing our lines onto the FVB strain. For multiple lines we have achieved 5th generation backcross and are beginning to characterize these animals for transgenic phenotype.

We intend to cross our transgenic lines with reporter lines generated in this lab designated HLL (24). The HIV-1 LTR has been extensively characterized as a NF- $\kappa$ B responsive promoter (25). These lines carry the NF- $\kappa$ B responsive human immunodeficiency virus-1 long terminal repeats, HIV-LTR, promoter fused to luciferase which enables direct analysis of the expression of an *in vivo* NF- $\kappa$ B reporter. This will provide an extremely valuable system which will allow us to determine whether expression of I $\kappa$ B $\Delta$ N is blocking NF- $\kappa$ B activity *in vivo*. Such crosses will also determine whether the overexpression of NF $\kappa$ B2 results in an active transcription factor or whether the full length protein (p100) is behaving as an inhibitor of other NF- $\kappa$ B complexes and thus, preventing transcriptional activation. An initial pilot study with a very limited number of animals appears promising. HLL transgenic animals at 16.5 days of pregnancy produce 1106  $\pm$  288 relative light units/ $\mu$ g of protein. Mice carrying the MAN transgene in addition to the HLL transgene at the same stage produce 537 $\pm$  268 rlu/ $\mu$ g protein. This relative decrease in measured luciferase activity suggests that the MAN transgene is able to inhibit NF- $\kappa$ B activity. Expansion of this study is underway.

The FVB strain background is believed to be more susceptible to tumor formation than the current B6/D2 strain background. In addition very limited effects of leaky transgene expression would be expected in virgin animals (as the promoter used normally directs expression of a milk protein). Thus we were surprised on examining haematoxylin and eosin stained sections from older, virgin BIN transgenic animals to note some morphological differences relative to control glands (Figure 5). This may be an indication of future more profound effects on older animals on the FVB strain background after a couple of rounds of pregnancy.

### **CONCLUSIONS**

Analysis of the transgenic lines is in progress. Indications are that the transgenes are able to perturb NF-kB activity at different stages but further studies are required to determine the nature of these alterations. No profound effect on the ability of either transgene to alter milk protein production has been detected. Suspected effects on proliferation are proving difficult to confirm. A degree of variation between animals is apparent, possibly exacerbated by the fact that our transgenics are on a B6/D2 background ie. a mixture between C57Bl6 and DBA strains. We have backcrossed our animals onto the FVB strain to alleviate any potential difficulties associated with such variation and are continuing characterizations on this genetic background. In addition FVB backcrosses were required for proposed tumorigenesis studies.

We are extremely interested in determining whether the transgenes are expressed consistently across entire glands or whether some degree of mosaic expression may be present and are generating antibodies for these studies.

At this stage indications are that the transgenes differentially affect NFkB complex formation and activity. More information is necessary before it can be determined whether disregulation of NF-kB complex formation results in altered regulation of gene products leading to unscheduled growth, misregulated differentiation, altered rates of apoptosis, excess angiogenesis or invasiveness.

In summary, in relation to the original statement of work, samples collected for technical objective 1 have been included in the results reported for award #DAMD17-97-1-7017. Tasks 2-4 of technical objective 2 have been completed and characterization as per Tasks 5-7 is underway. A small pilot study representing Task 8 has been completed.

### REFERENCES

- 1. Parker, S.L., Tong, T., Bolden, S., and Wingo, P.A. 1996. Cancer Statistics, 1996. CA: A Journal of the American Cancer Society 46(1); 5-27.
- Verma, I.M., Stevenson, J.K., Schwarz, E.M., Van Antwerp, D., and Miyamoto, S. 1995. Rel/NF-κΒ/IκB family: intimate tales of association and dissociation. Genes and Devel. 9:2723-2735.
- 3. Kerr, L.D. and Verma, I.M. 1992. Signal transduction: The nuclear target. Curr. Opin. Cell Biol. 4: 496-501.
- 4. Gilmore, T.D., Koedood, M., Piffat, K.A. And White, D.W. 1996. Rel/NF-κB/IκB proteins and cancer. Oncogene 13: 1367-1378.
- 5. Dejardin, E., Bonizzi, G., Bellahcene, A., Castronovo, V., Merville, M.-P., and Bours, V. 1995. Highly-expressed p100/p52 (NFκB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11: 1835-1841.
- 6. Nolan, G.P., Baltimore, D. 1992. The inhibitory ankyrin and activator rel proteins. Curr. Opin. Genet. Dev. 2: 211-220.
- 7. Ghosh, S., Gifford, A.M., Riviere, L.R., Tempst, P., Nolan, G.P., and Baltimore, D. 1990. Cloning of the p50 DNA binding subunit of NF-κB: Homology to *rel* and *dorsal*. Cell 62: 1019-1029.
- 8. Nolan, G.P., Ghosh, S., Liou, H.-C., Tempst, P., Baltimore, D. 1991. DNA binding and IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 64: 961-969.
- 9. Bull, P. Morley, K.L., Hoekstra, M.F., Hunter, T., Verma, I.M. 1990. The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol. Cell. Biol. 10: 5473-5485.
- 10. Scheinman, R.I., Beg, A.A., and Baldwin, A.S. 1993. NF-κB p100 (Lyt-10) is a component of HSTF1 and can function as an IκB-like molecule. Mol. Cell. Biol. 13: 6089-6101.
- Brockman, J.A., Scherer, D.C., McKinsey, T.A., Hall, S.M., Qi, X., Lee, W.Y., Ballard, D.W. 1995. Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol. Cell. Biol. 15: 2809-2818.
- 12. Treanckner, E. B.-M., Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S., Baeuerle, P.A. 1995.
  Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14: 2876-2883.
- 13. Chen, C-L, Yull, F.E. And Kerr, L.D. 1999. Differential serine phosphorylation regulates IκB-α inactivation. Biochem. Biophys. Res. Comm. 257: 798-806.

- 14. Inoue, J.-i., Kerr, L.D., Rashid, D., Davis, N., Bose, H.R., Verma, I.M. 1992. Direct association of pp40/IkBβ with rel/NF-κB transcription factors: Role of ankyrin repeats in the inhibition of DNA binding activity. Proc. Natl. Acad. Sci USA 89: 4333-4337.
- Bushdid, P.B., Brantley, D.M., Yull, F.E., Blaeuer, G.L., Hoffman, L.H., Niswander, L. and Kerr, L.D. 1998. Inhibition of NF-κB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature 392: 615-618.
- 16. Mercurio, F., DiDonato, J., Rosette, C., and Karin, M. 1992. Molecular cloning and characterization of a novel Rel/NF-κB family member displaying structural and functional homology to NF-κB/p50/p105. DNA Cell Biol. 11: 523-537.
- 17. Zang, J., Chang, C.-C., Lombardi, L., and Dalla-Favera, R. 1994. Rearranged NFKB2 gene in the HUT78 T-lymphoma cell line codes for a constitutively nuclear factor lacking transcriptional repressor functions. Oncogene 10: 1931-1937.
- 18. Simons, J.P., McClenaghan, M. and Clark, A.J. 1987. Alteration of the quality of milk by expression of sheep B-lactoglobulin in transgenic mice. Nature 328: 530-532.
- 19. Harris, S., McClenaghan, M., Simons, J.P., Ali, S. and Clark, A.J. 1991. Developmental regulation of the sheep beta-lactoglobulin gene in the mammary gland of transgenic mice. Developmental Genetics 12: 299-307.
- 20. Archibald, A.L., McClenaghan, M., Hornsey, V., Simons, J.P. and Clark, A.J. 1990. High level expression of biologically active human α1-antitrypsin in transgenic mice. Proc. Natl. Acad. Sci. USA 87: 5178-5182.
- 21. Whitelaw, C.B.A., Harris, S., McClenaghan, M., Simons, J., and Clark, A.J. 1992. Position-independent expression of the ovine β-lactoglobulin gene in transgenic mice. Biochem. J. 286: 31-39.
- Yull, F., Harold, G., Wallace, R., Cowper, A., Percy, J., Cottingham, I., and Clark, A.J. 1995. Fixing human factor IX (fIX): Correction of a cryptic RNA splice enables the production of biologically active fIX in the mammary gland of transgenic mice. Proc. Natl. Acad. Sci. USA 92: 10899-10903.
- 23. Brantley, D.M., Yull, F.E., Hicks, D., Cook, C.M. and Kerr, L.D. Dynamic expression and activity of NF-κB during post-natal mammary gland morphogenesis. (Submitted).
- 24. Blackwell, T.S., Yull, F.E., Chen, C-L, Venkatakrishnan, A., Blackwee, T.R., Hicks, D.J., Lancaster, L.H., Christman, J.W. and Kerr, L.D. 1998. NF-κB activation and cytokine production in a transgenic mouse model of endotoxin-induced lung inflammation. J. Exp. Med. (Submitted).
- 25. Kretzschmar, M., Meisterernst, M., Scheidereit, C., Li, G., Roeder, R.G. 1992. Transcriptional regulation of the HIV-1 promoter by NF-κB. Genes. & Devel. 6:761-774.

# Appendices

## Key Research Accomplishments

- 1) Generation of four lines of transgenic mice expressing a dominant inhibitor of NF $\kappa$ B (I $\kappa$ B $\Delta$ N).
- 2) Generation of four lines of mice carrying a mammary specific p100 transgene.
- 3) Basic characterization of lines.
- 4) Accumulation of major repository of tissue, RNA, protein, whole mount and paraffin section samples.

Figure 1 : Northern Analysis of Transgene /  $\beta$ -Casein Expression

Figure a




Figure b




Figure 2: NF-κB Binding Activity in Transgenics

Figure a




Figure b




Figure 3: BrdU incorporation at 16.5dpc/BIN transgenics






Figure 4: BrdU incorporation 16.5dpc/MAN transgenics



# Figure 5: H&E of old mammary




Non-Transgenic vir 10 months



BIN 10 vir 12 months



BIN 18 vir 11 months



BIN 16 vir 10 months